{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:18:14Z","timestamp":1783491494594,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spinal muscular atrophy (SMA) is a severe neuromuscular disease characterized by respiratory muscle weakness, often leading to high mortality. Research on the effect of nusinersen on respiratory function in SMA patients remains scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate nusinersen's effect on respiratory function in SMA patients and provide a clinical basis for respiratory management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center prospective study, clinical data were collected from SMA patients in our pediatric department. Respiratory function, expressed as absolute values and percentages of predicted values (%pred), and active cough strength was evaluated at baseline and during follow-up after nusinersen treatment. Treatment effects were subsequently analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 59 SMA patients (39 Type II; 20 Type III), 40 completed baseline respiratory tests, of whom 67.5% had abnormal respiratory function. Type II patients had significantly lower VC %pred, FVC %pred, FEV1%pred, PEF %pred, FEF25%pred, and FEF50%pred than Type III patients (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). After 6 months, absolute value of FVC improved significantly in Type III (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05); by 18 months, absolute VC values in Type II patients, and absolute values and %pred of VC, FVC, FEF25, FEF50, and FEF75 in Type III increased significantly (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Ineffective cough was observed in 76.3% of patients at baseline, and was more common in Type II patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). Among patients who completed 18-month respiratory function follow-up (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923), the proportion with effective cough increased significantly from 39.1% (9\/23) at baseline to 56.5% (13\/23) after treatment (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most SMA patients had impaired respiratory function, which was more severe in Type II than Type III patients. Nusinersen improved respiratory function and active cough strength, but could not fully reverse the progression of restrictive ventilatory dysfunction, especially in Type II.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1874241","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:54:25Z","timestamp":1783490065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of nusinersen on respiratory function in patients with spinal muscular atrophy: an 18-month single-center prospective study"],"prefix":"10.3389","volume":"14","author":[{"given":"Tianjian","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University","place":["Guangzhou, China"]},{"name":"Department of Pediatrics, Foshan Women and Children Hospital","place":["Foshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejpn.2024.06.001","article-title":"2024 Update: european consensus statement on gene therapy for spinal muscular atrophy","volume":"51","author":"Kirschner","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","article-title":"Natural history of lung function in spinal muscular atrophy","volume":"15","author":"Wijngaarde","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ppul.25142","article-title":"Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen","volume":"56","author":"G\u00f3mez-Garc\u00eda De La Banda","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/thoraxjnl-2020-216564","article-title":"Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1\u20133","volume":"77","author":"Chacko","year":"2022","journal-title":"Thorax"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e15175","DOI":"10.1111\/ped.15175","article-title":"Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen","volume":"64","author":"Ergenekon","year":"2022","journal-title":"Pediatr Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e15310","DOI":"10.1111\/ped.15310","article-title":"The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy","volume":"64","author":"Hepkaya","year":"2022","journal-title":"Pediatr Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.7499\/j.issn.1008-8830.2401082","article-title":"Clinical efficacy of nusinersen sodium in the treatment of children with spinal muscular atrophy","volume":"45","author":"ZHU Yiwen","year":"2023","journal-title":"Guangxi Med J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1372674","DOI":"10.3389\/fneur.2024.1372674","article-title":"Respiratory function in adult patients with spinal muscular atrophy treated with nusinersen - a monocenter observational study","volume":"15","author":"Wurster","year":"2024","journal-title":"Front Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1007\/s00415-023-11711-4","article-title":"An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy","volume":"270","author":"Bjelica","year":"2023","journal-title":"J Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/s0960-8966(06)80015-5","article-title":"International SMA consortium meeting. (26\u201328 June 1992, bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscular Disord"},{"key":"B16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"B17","first-page":"744","article-title":"Pulmonary function collaboration group of the respiratory group PBOT: series of guidelines for pediatric pulmonary function (II): pulmonary volume and ventilation function","volume":"31","year":"2016","journal-title":"Chin J Appl Clin Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1378\/chest.120.4.1262","article-title":"Predictors of extubation outcome in patients who have successfully completed a spontaneous breathing trial","volume":"120","author":"Khamiees","year":"2001","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","article-title":"Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study","volume":"96","author":"Trucco","year":"2021","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.chest.2023.03.011","article-title":"Respiratory management of patients with neuromuscular weakness: an American college of chest physicians clinical practice guideline and expert panel report","volume":"164","author":"Khan","year":"2023","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7499\/j.issn.1008-8830.2401082","article-title":"Chinese Pediatricians association CRGO: expert consensus on respiratory management of spinal muscular atrophy (2022 edition) of the Chinese pediatricians association","volume":"37","year":"2022","journal-title":"Chin J Appl Clin Pediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"B23","first-page":"914","article-title":"Analysis of pulmonary function in patients with spinal muscular atrophy","volume":"37","author":"JIANG Yuan","year":"2022","journal-title":"Chin J Appl Clin Pediatr"},{"key":"B24","first-page":"211","article-title":"Changes in pulmonary function and their clinical significance in children with spinal muscular atrophy","volume":"57","author":"Shuzheng Qiaoyan","year":"2023","journal-title":"J Fujian Med Univ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-022-02227-7","article-title":"Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study","volume":"17","author":"Veldhoen","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1038\/s41598-025-32566-x","article-title":"Inspiratory muscle training and trunk control exercises on respiratory strength and motor function in spinal muscular atrophy: randomized controlled trial","volume":"16","author":"Ata","year":"2025","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e214982","DOI":"10.1212\/WNL.0000000000214982","article-title":"Lung function and respiratory muscle strength in symptomatic children and adults with spinal muscular atrophy treated with nusinersen","volume":"106","author":"Vercoelen","year":"2026","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.gene.2012.12.109","article-title":"Molecular analysis of SMN1, SMN2, NAIP, GTF2H2, and H4F5 genes in 157 Chinese patients with spinal muscular atrophy","volume":"518","author":"He","year":"2013","journal-title":"Gene"},{"key":"B31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/0883073814553271","article-title":"Association of copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein gene with the natural history in a Chinese spinal muscular atrophy cohort","volume":"30","author":"Qu","year":"2015","journal-title":"J Child Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1002\/ppul.24760","article-title":"Lung ultrasound: a useful additional tool in clinician\u2019s hands to identify pulmonary atelectasis in children with neuromuscular disease","volume":"55","author":"Ullmann","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"B34","doi-asserted-by":"publisher","year":"","DOI":"10.1186\/S13023-022-02227-7"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1874241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:54:29Z","timestamp":1783490069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1874241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":34,"alternative-id":["10.3389\/fped.2026.1874241"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1874241","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1874241"}}